MonoMethyl auristatin F

Research use only, not for human use.

Monomethyl auristatin F, an antimitotic agent, inhibits cell division by blocking the polymerization of tubulin.

Monomethyl auristatin F (MMAF) is a synthetic antineoplastic agent. It is part of some experimental anti-cancer antibody-drug conjugates such as vorsetuzumab mafodotin and SGN-CD19A. In International Nonproprietary Names for MMAF-antibody-conjugates, the name mafodotin refers to MMAF plus its attachment structure to the antibody. MMAF is actually desmethyl-auristatin F; that is, the N-terminal amino group has only one methyl substituent instead of two as in auristatin F itself.

——

——

Monomethyl auristatin F | MMAF

Cell Cycle/DNA Damage

Potassium Channel

Cytotoxicity( Karpas 299 cell)

Cancer

——

745017-94-1

731.98

C39H65N5O8

>98% (HPLC)

——

CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@@H]([C@@H](C)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)OC)OC)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC

((2R,3R)-3-((2S)-1-((3R,5S)-4-((S)-N,3-dimethyl-2-((S)-3-methyl-2-(methylamino)butanamido)butanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanoyl)-L-phenylalanine

(-20℃)

With Ice Pack

≥ 2 years